New PET scans could sharpen bladder cancer diagnosis

NCT ID NCT06421142

Recruiting now Diagnosis Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three imaging methods—FAPI PET/MRI, FDG PET/MRI, and MRI—to see which best detects muscle-invasive bladder cancer and tracks how well pre-surgery treatment works. Researchers will enroll 80 participants with suspected or confirmed bladder cancer. The goal is to improve accuracy so doctors can tailor treatments more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI and 18F-FDG tracers (imaging agents)
What this could lead to: If successful, this could lead to more accurate diagnosis of muscle-invasive bladder cancer and better prediction of whether neoadjuvant therapy is working, helping doctors adjust treatment sooner.
What could go wrong: This is a small, early-stage study (80 participants) focused on imaging accuracy, not treatment. The results may not apply to all patients, and the imaging techniques are not yet standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY BLADDER NEOPLASMS

Contacts and locations

Locations

first hospital affiliated of Fujian medical university
RECRUITING

Fuzhou, Fujian, 350005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.